Allergan, makers of Botox, endorses Z160 for Post-Herpetic Neuralgia (PHN)
Zalicus is advancing Z160 into Phase 2 clinical development for chronic neuropathic pain associated with Lumbosacral Radiculopathy (LSR) and Post-Herpetic Neuralgia (PHN).
Syntaxin's partner Allergan has begun two Phase 2 trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868. The Phase II trials will evaluate the drug candidate in patients with Post-Herpetic Neuralgia (PHN). The drug targets sensory neurones involved in pain transmission.
Zalicus and Allergan are going after the SAME source of pain. Who knows more about pain? Justin Renz, Jason Napodano, or Allergan??? I would go with Allergan. PHN must be a great choice to evaluate analgesia.
According to Garrett, Justin Renz was subtly suggest Lumbosacral Radiculopathy (LSR) was a better indication for Z160. However, Allergan chose Post-Herpetic Neuralgia (PHN) as their pain indication for targeting sensory neurons involved in pain transmission. My conclusion is that Allergan concurs with Terry Snutch and Mark Corrigan that PHN is an equally good indication for evaluating new analgesics that target sensory neurons. I do not agree that one indication is better than the other until we have the data, which I assure you Justin does not have because its blinded.
Second question. Do we have competition with Allergan and Icagen/Pfizer? Yes we do, so Z160 BETTER BE BETTER!!! Or, we will get taken to the wood shed.